PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT03064854
- Locations
- 🇺🇸
UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica, California, United States
🇺🇸Henry Ford Health System SC, Detroit, Michigan, United States
🇺🇸Stanford Cancer Center SC, Stanford, California, United States
Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.
- Conditions
- Asthma
- Interventions
- Drug: QVM149 150/50/80 μg o.d.Drug: QVM149 150/50/160 μg o.d.Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d.
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 116
- Registration Number
- NCT03063086
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
- Conditions
- Atherosclerotic Cardiovascular DiseaseSymptomatic AtherosclerosisType2 DiabetesFamilial Hypercholesterolemia
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 382
- Registration Number
- NCT03060577
- Locations
- 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 379
- Registration Number
- NCT03056755
- Locations
- 🇺🇸
Kaiser Permanente Medical Group, Anaheim, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
- Conditions
- Plaque Psoriasis
- Interventions
- Biological: PlaceboBiological: Secukinumab
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 102
- Registration Number
- NCT03055494
- Locations
- 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
- Conditions
- Asthma
- Interventions
- Drug: QAW039 150 mgDrug: QAW039 450 mgDrug: Placebo
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2538
- Registration Number
- NCT03052517
- Locations
- 🇬🇧
Novartis Investigative Site, Leicester, United Kingdom
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT03050398
- Locations
- 🇺🇸
PeaceHealth St Joseph Medical Center, Bellingham, Washington, United States
🇺🇸Arizona Oncology Associates PC HAL, Sedona, Arizona, United States
🇺🇸Oncology Speciialists of Charlotte, Charlotte, North Carolina, United States
Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT03048448
- Locations
- 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
- Conditions
- Advanced Solid Tumors Which Are cMET-dependent
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03040973
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
- Conditions
- Juvenile Psoriatic ArthritisEnthesitis-related Arthritis
- Interventions
- Other: placebo
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT03031782
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom